Stacy Lindborg, PhD, on the Upcoming FDA Advisory Committee Meeting for NurOwn in ALS
The co-CEO of BrainStorm Cell Therapeutics spoke on the supporting data for the investigational ALS cell therapy that will be discussed at the meeting, and expectations for it.
“We are encouraged by the regulatory flexibility the FDA is showing in ALS... FDA flexibility is good for patients in these fatal illnesses and these rapidly progressing illnesses, such as ALS. It's good for science, as it allows us to learn more rapidly as a community in ALS drug development. We are confident in the effectiveness of NurOwn and we're grateful to the FDA for the opportunity to review the full body of clinical evidence.”
BrainStorm Cell Therapeutics has announced an upcoming Advisory Committee Meeting with the FDA to discuss its biologics license application for NurOwn, an autologous bone marrow-derived mesenchymal stem cell therapy which was evaluated for the treatment of amyotrophic lateral sclerosis (ALS) in a phase 3 clinical trial (NCT03280056). Of particular importance for this meeting is the floor effect: the ALS Functional Rating Scale cannot measure disease progression after a certain point in patients with advanced ALS.
In an interview with CGTLive™, Stacy Lindborg, PhD, the co-CEO of BrainStorm Cell Therapeutics, spoke about the upcoming meeting and gave an overview of the relevant clinical trial data, including data which were recently presented at the
REFERENCE
1. Brainstorm Cell Therapeutics announces FDA advisory committee meeting to review biologics license application for NurOwn® for the treatment of ALS. News release. BrainStorm Cell Therapeutics Inc. March 27, 2023. Accessed March 27, 2023. https://ir.brainstorm-cell.com/2023-03-27-BrainStorm-Cell-Therapeutics-Announces-FDA-Advisory-Committee-Meeting-to-Review-Biologics-License-Application-for-NurOwn-R-for-the-Treatment-of-ALS
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025